Elucidata Corporation partnered with Auron Therapeutics to identify and validate therapeutic targets for Acute Myeloid Leukemia (AML) and eight other oncology indications (originally announced here).The collaboration leveraged Elucidata's data-centric AI Platform to advance Auron's differentiation-based approach to cancer treatment.

The initiative enabled large-scale integration and analysis of transcriptomic, metabolomic, and epigenetic data alongside patient disease profiles and treatment response information. This multi-omics framework allowed healthy and diseased cellular states to be characterized at high molecular resolution, revealing actionable biological insights that are difficult to uncover using conventional approaches. Auron contributed rich phenotypic data and multi-omics datasets from hundreds of patient samples. Combined with Polly’s advanced computational methods, this analysis supported the identification and validation of novel therapeutic targets, improved stratification of cancer subtypes, and more precise matching of targets to patient subgroups-laying the foundation for therapies with higher efficacy and fewer side effects.

As an outcome of this collaboration, Elucidata’s target discovery approach helped them assess 10 differentiation targets for Acute Myeloid Leukemia (AML) in just six months, demonstrating its long-term potential. Elucidata’s focused strategy on target, indication, and modalities, leveraging multi-omics data was used to create an advanced knowledge graph for faster summarization, retrieval, and visualization. This approach delivered a comprehensive target-indication assessment report, offering a 360-degree view of targets and disease biology, empowering the company to make data-driven, informed decisions.

Read more in detail: Cancer Novel Target Identified and Advanced to Trials 4× Faster

‍

About Auron Therapeutics‍

Auron Therapeutics was founded in 2018 to develop therapies that cure cancer by changing the paradigm from cell killing to transforming malignant cells into normal cells. This approach, called differentiation therapy, reactivates cellular programs to drive tumor cell maturation and convert cancer into normal tissue. Its platforms integrate large-omic datasets with miniaturized high-throughput flow cytometry to rapidly identify and validate targets and drugs in primary human patient sampl